MicuRx will Receive $5.2 Million to Advance Drug-Resistant Antibiotic
MicuRx Pharma, a San Francisco-Shanghai anti-infective company, announced it will receive up to $5.2 million in non-dilutive financing from a global partnership: Combating Antibiotic Resistant Bacteria Accelerator (CARB-X). MicuRx will use the money to produce an IND and then conduct Phase I trials of MRX-8, a novel polymyxin antibiotic designed to treat multi-drug resistant Gram-negative infections. In preclinical tests, MRX-8 was effective with a lower incidence of the side effects caused by other products in the class. More details....
Share this with colleagues:
Original Article: MicuRx will Receive $5.2 Million to Advance Drug-Resistant Antibiotic
NEXT ARTICLE
More From BioPortfolio on "MicuRx will Receive $5.2 Million to Advance Drug-Resistant Antibiotic"
